Current label answer
Wegovy weekly-injection trials report constipation in 24% versus 11% with placebo
The Wegovy prescribing information updated June 18, 2026 covers both subcutaneous injection and once-daily tablets. In pooled adult weight-management trials of the 2.4 mg once-weekly injection, constipation was reported in 24% of Wegovy-treated participants and 11% of placebo participants. The label says the types and frequency of common adverse reactions in the Wegovy 25 mg tablet trial were similar to those in the injection table, but it does not publish a tablet-specific constipation percentage in that table. These data establish a recognized association in the studied populations without predicting one person’s cause, severity, or duration.
- Keep the 24% versus 11% comparison tied to pooled adult trials of branded Wegovy 2.4 mg weekly injection.
- Do not present the injection percentage as a tablet-specific rate or transfer it to Ozempic, another indication or strength, or compounded semaglutide.
- A group-level trial percentage cannot determine whether semaglutide caused an individual bowel change or how long that symptom should last.
Symptom pattern and urgency
Routine bowel changes and obstruction-like symptoms need different pathways
Constipation can mean fewer bowel movements, harder stools, straining, incomplete emptying, or a meaningful change from a person’s usual pattern. Current Wegovy labeling also lists postmarketing reports of ileus, intestinal obstruction, and severe constipation including fecal impaction. Because voluntary reports come from a population of uncertain size, they do not provide a frequency or prove semaglutide caused an individual event. They do support taking severe, progressive, or obstruction-like symptoms seriously rather than assuming every bowel change is routine.
- Record the last bowel movement, stool consistency, ability to pass gas, abdominal swelling, pain location and severity, nausea or vomiting, fever, bleeding, food and fluid intake, and urine output.
- Contact the prescriber for a persistent or worsening change, painful bowel movements, marked straining, symptoms after a refill or clinician-directed change, or constipation that affects eating, drinking, sleep, work, or diabetes care.
- Seek prompt in-person assessment for severe or persistent abdominal pain, repeated vomiting, marked swelling or a rigid abdomen, inability to pass stool or gas, blood or black stool, fainting, confusion, severe weakness, or inability to keep fluids down.
Medication and medical review
Other medicines, low intake, and prior bowel conditions may change the assessment
A bowel-pattern change may overlap with reduced food or fluid intake, travel, illness, pregnancy, a prior gastrointestinal condition, or another medicine. Opioid pain medicines, iron, some antacids, anticholinergic medicines, some antidepressants, antihistamines, and other products can contribute to constipation for some people. A clinician should review the full pattern instead of assuming semaglutide is the only possible cause or automatically recommending the same remedy to everyone.
- Share prior constipation, bowel obstruction or surgery, hernia, severe gastroparesis, pelvic-floor problems, kidney or heart disease, pregnancy possibility, recent illness, and meaningful changes in food, fluid, activity, or weight.
- List every prescription, over-the-counter medicine, vitamin, mineral, fiber product, laxative, antacid, pain medicine, antihistamine, supplement, alcohol product, and cannabis product.
- Do not combine laxatives, use repeated enemas, start a “detox,” or follow a forum clean-out plan without individualized clinician or pharmacist guidance.
Product identity and evidence boundary
Branded Wegovy data do not establish a compounded-semaglutide constipation rate
Wegovy and Ozempic are FDA-approved finished semaglutide products with product-specific indications, routes, presentations, instructions, and evidence. A patient-specific compounded semaglutide preparation is not an FDA-approved finished drug product and may differ in concentration, inactive ingredients, container, labeling, storage, and beyond-use date. Constipation after a refill or product change should prompt verification of the exact product label and dispensing pharmacy rather than an assumption that every pen, tablet, or vial is interchangeable.
- Bring the product name, indication, route, strength or concentration, manufacturer or dispensing pharmacy, prescriber, refill or lot details, storage history, and a photo of the current label.
- Contact the responsible prescriber before skipping, repeating, stopping, restarting, splitting, increasing, decreasing, or converting between a tablet and injection.
- Avoid research-use products, unlabeled vials, counterfeit pens or tablets, copied syringe or bowel-cleanout charts, and sellers that provide semaglutide without prescription-first clinician review.
Follow-up plan
A safe plan is individualized and includes a clear escalation pathway
For non-emergency constipation, the prescriber can review symptoms, hydration and nutrition, other medicines, medical history, and the exact semaglutide product before deciding whether examination, testing, a bowel-management plan, or a treatment change is appropriate. Generic advice to drink more, add fiber, or take a laxative may not fit someone with vomiting, severe pain, obstruction-like symptoms, fluid restrictions, kidney disease, pregnancy, or medication interactions.
- Ask which food, fluid, activity, or bowel-product steps fit the individual medical history and when lack of improvement should trigger reassessment.
- Ask whether glucose, kidney function, hydration, pregnancy, abdominal examination, imaging, or another evaluation is relevant to the actual symptom pattern.
- Know whether to use routine messaging, same-day clinical guidance, urgent care, or emergency services before symptoms worsen.